{"id":"NCT03019783","sponsor":"Brigham and Women's Hospital","briefTitle":"Atazanavir and Endothelial Function in Older HIV Patients","officialTitle":"Atazanavir and Endothelial Function in Older HIV Patients","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2011-12","primaryCompletion":"2015-06","completion":"2016-06","firstPosted":"2017-01-13","resultsPosted":"2017-04-18","lastUpdate":"2017-05-16"},"enrollment":60,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"BASIC_SCIENCE"},"conditions":["HIV"],"interventions":[{"type":"DRUG","name":"Atazanavir","otherNames":["Reyataz"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Remains on baseline HIV regimen","type":"PLACEBO_COMPARATOR"},{"label":"Atazanavir switch","type":"ACTIVE_COMPARATOR"}],"summary":"The investigators hypothesize that older subjects with HIV randomly assigned to atazanavir will have increased bilirubin levels, reduced oxidative stress, and improved flow-mediated, endothelium-dependent vasodilation compared to subjects not switched to atazanavir.","primaryOutcome":{"measure":"Change in Flow-mediated, Endothelium-dependent Vasodilation","timeFrame":"4 weeks","effectByArm":[{"arm":"Remains on Baseline HIV Regimen","deltaMin":0.2,"sd":2.4},{"arm":"Atazanavir Switch","deltaMin":0.8,"sd":4.6}],"pValues":[]},"eligibility":{"minAge":"45 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":5},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["29023508"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":29},"commonTop":[]}}